Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
1.
Reprod Health ; 14(1): 82, 2017 Jul 11.
Article in English | MEDLINE | ID: mdl-28693525

ABSTRACT

BACKGROUND: Malawi introduced an ambitious public health program known as "Option B+" which provides all HIV-infected pregnant and breastfeeding women with lifelong combination antiretroviral therapy, regardless of WHO clinical stage or CD4 cell count. The PMTCT Uptake and REtention (PURE) study aimed at evaluating the effect of peer-support on care-seeking and retention in care. METHODS/DESIGN: PURE Malawi was a three-arm cluster randomized controlled trial that compared facility-based and community-based models of peer support to standard of care under Option B+ strategy. Each arm was expected to enroll a minimum of 360 women with a total minimum sample size of 1080 participants. 21 sites (clusters) were selected for inclusion in the study. This paper describes the site selection, recruitment, enrollment process and baseline characteristics of study sites and women enrolled in the trial. RESULTS: Study implementation was managed by 3 partner organizations; each responsible for 7 study sites. The trial was conducted in the South East, South West, and Central West zones of Malawi, the zones where the implementing partners operate. Study sites included 2 district hospitals, 2 mission hospitals, 2 rural hospitals, 13 health centers and 1 private clinic. Enrollment occurred from November 2013 to November 2014, over a median period of 31 weeks (range 17-51) by site. A total of 1269 HIV-infected pregnant (1094) and breastfeeding (175) women, who were eligible to initiate ART under Option B+, were enrolled. Each site reached or surpassed the minimum sample size. Comparing the number of women enrolled versus antenatal cohort reports, sites recruited a median of 90% (IQR 75-100) of eligible reported women. In the majority of sites the ratio of pregnant and lactating women enrolled in the study was similar to the ratio of reported pregnant and lactating women starting ART in the same sites. The median age of all women was 27 (IQR 22-31) years. All women have ≥20 months of possible follow-up time; 96% ≥ 2 years (24-32 months). CONCLUSION: The PURE Malawi study showed that 3 implementing partner organizations could successfully recruit a complex cohort of pregnant and lactating women across 3 geographical zones in Malawi within a reasonable timeline. TRIAL REGISTRATION: This study is registered at clinicaltrials.gov - ID Number NCT02005835 . Registered 4 December, 2013.


Subject(s)
Anti-Retroviral Agents/therapeutic use , HIV Infections/transmission , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/drug therapy , Public Health , Social Support , Adult , Anti-Retroviral Agents/pharmacokinetics , Female , HIV Infections/drug therapy , Humans , Malawi , Pregnancy
2.
J Acquir Immune Defic Syndr ; 75 Suppl 2: S140-S148, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28498183

ABSTRACT

BACKGROUND: Many sub-Saharan African countries have adopted Option B+, a prevention of mother-to-child transmission approach providing HIV-infected pregnant and lactating women with immediate lifelong antiretroviral therapy. High maternal attrition has been observed in Option B+. Peer-based support may improve retention. METHODS: A 3-arm stratified cluster randomized controlled trial was conducted in Malawi to assess whether facility- and community-based peer support would improve Option B+ uptake and retention compared with standard of care (SOC). In SOC, no enhancements were made (control). In facility-based and community-based models, peers provided patient education, support groups, and patient tracing. Uptake was defined as attending a second scheduled follow-up visit. Retention was defined as being alive and in-care at 2 years without defaulting. Attrition was defined as death, default, or stopping antiretroviral therapy. Generalized estimating equations were used to estimate risk differences (RDs) in uptake. Cox proportional hazards regression with shared frailties was used to estimate hazard of attrition. RESULTS: Twenty-one facilities were randomized and enrolled 1269 women: 447, 428, and 394 in facilities that implemented SOC, facility-based, and community-based peer support models, respectively. Mean age was 27 years. Uptake was higher in facility-based (86%; RD: 6%, confidence interval [CI]: -3% to 15%) and community-based (90%; RD: 9%, CI: 1% to 18%) models compared with SOC (81%). At 24 months, retention was higher in facility-based (80%; RD: 13%, CI: 1% to 26%) and community-based (83%; RD: 16%, CI: 3% to 30%) models compared with SOC (66%). CONCLUSIONS: Facility- and community-based peer support interventions can benefit maternal uptake and retention in Option B+.


Subject(s)
Anti-HIV Agents/therapeutic use , Community Health Services , HIV Infections/drug therapy , Health Services Accessibility/organization & administration , Infectious Disease Transmission, Vertical/prevention & control , Mothers , Pregnancy Complications, Infectious/drug therapy , Adult , Antiretroviral Therapy, Highly Active/methods , Cluster Analysis , Community Health Services/organization & administration , Female , HIV Infections/prevention & control , HIV Infections/transmission , Health Services Research , Humans , Malawi/epidemiology , Peer Group , Pregnancy , Pregnancy Complications, Infectious/prevention & control , Program Evaluation , Social Support , Young Adult
3.
J Acquir Immune Defic Syndr ; 75 Suppl 2: S149-S155, 2017 06 01.
Article in English | MEDLINE | ID: mdl-28498184

ABSTRACT

BACKGROUND: In 2011, Malawi launched Option B+, a program of universal antiretroviral therapy (ART) treatment for pregnant and lactating women to optimize maternal health and prevent pediatric HIV infection. For optimal outcomes, women need to achieve HIVRNA suppression. We report 6-month HIVRNA suppression and HIV drug resistance in the PURE study. METHODS: PURE study was a cluster-randomized controlled trial evaluating 3 strategies for promoting uptake and retention; arm 1: Standard of Care, arm 2: Facility Peer Support, and arm 3: Community Peer support. Pregnant and breastfeeding mothers were enrolled and followed according to Malawi ART guidelines. Dried blood spots for HIVRNA testing were collected at 6 months. Samples with ART failure (HIVRNA ≥1000 copies/ml) had resistance testing. We calculated odds ratios for ART failure using generalized estimating equations with a logit link and binomial distribution. RESULTS: We enrolled 1269 women across 21 sites in Southern and Central Malawi. Most enrolled while pregnant (86%) and were WHO stage 1 (95%). At 6 months, 950/1269 (75%) were retained; 833/950 (88%) had HIVRNA testing conducted, and 699/833 (84%) were suppressed. Among those with HIVRNA ≥1000 copies/ml with successful amplification (N = 55, 41% of all viral loads > 1000 copies/ml), confirmed HIV resistance was found in 35% (19/55), primarily to the nonnucleoside reverse transcriptase inhibitor class of drugs. ART failure was associated with treatment default but not study arm, age, WHO stage, or breastfeeding status. CONCLUSIONS: Virologic suppression at 6 months was <90% target, but the observed confirmed resistance rates suggest that adherence support should be the primary approach for early failure in option B+.


Subject(s)
Anti-HIV Agents/therapeutic use , Drug Resistance/drug effects , HIV Infections/drug therapy , Infectious Disease Transmission, Vertical/prevention & control , Maternal-Child Health Services , Pregnancy Complications, Infectious/drug therapy , World Health Organization , Adult , Breast Feeding , CD4 Lymphocyte Count , Cluster Analysis , Female , HIV Infections/prevention & control , HIV Infections/transmission , Humans , Infant, Newborn , Malawi/epidemiology , Medication Adherence/statistics & numerical data , Pregnancy , Pregnancy Complications, Infectious/prevention & control , Program Evaluation , Viral Load , Young Adult
5.
BMC Health Serv Res ; 16: 136, 2016 04 19.
Article in English | MEDLINE | ID: mdl-27095249

ABSTRACT

BACKGROUND: Informal care, the health care provided by the patient's social network is important in low income settings although its monetary value is rarely estimated. The lack of estimates of the value of informal care has led to its omission in economic evaluations but this can result in incorrect decisions about cost effectiveness of an intervention. We explore the use of contingent valuation methods of willingness to pay (WTP) and willingness to accept (WTA) to estimate the value of informal care provided to HIV infected women that are accessing antiretroviral therapy (ART) under the Option B+ approach to prevention of mother-to-child transmission (PMTCT) of HIV in Malawi. METHODS: We collected cross sectional data from 93 caregivers of women that received ART care from six health facilities in Malawi. Caregivers of women that reported for ART care on the survey day and consented to participate in the survey were included until the targeted sample size for the facility was reached. We estimated the value of informal care by using the willingness to accept (WTA) and willingness to pay (WTP) approaches. Medians were used to summarize the values and these were compared by the Wilcoxon signed-rank test. RESULTS: The median WTA to provide informal care in a month was US$30 and the median WTP for informal care was US$13 and the two were statistically different (p < 0.000). Median WTP was higher in the urban areas than in the rural areas (US$21 vs. US$13, p < 0.001) and for caregivers from households from higher wealth quintile than in the lower quintile (US$15 vs. US$13, p < 0.0462). CONCLUSION: Informal caregivers place substantial value on informal care giving. In low income settings where most caregivers are not formally employed, WTP and WTA approaches can be used to value informal care. CLINICAL TRIAL NUMBER: NCT02005835.


Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/prevention & control , Infectious Disease Transmission, Vertical/prevention & control , Patient Care/economics , Pregnancy Complications, Infectious/prevention & control , Adult , Anti-HIV Agents/economics , Caregivers/economics , Cross-Sectional Studies , Female , HIV Infections/drug therapy , HIV Infections/economics , Health Expenditures/statistics & numerical data , Humans , Infectious Disease Transmission, Vertical/economics , Malawi , Male , Patient Acceptance of Health Care , Patient Care/standards , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Surveys and Questionnaires , Time Factors
6.
J Acquir Immune Defic Syndr ; 67 Suppl 2: S114-9, 2014 Nov 01.
Article in English | MEDLINE | ID: mdl-25310116

ABSTRACT

In July 2011, Malawi introduced an ambitious public health program known as "Option B+," which provides all HIV-infected pregnant and breastfeeding women with lifelong combination antiretroviral therapy, regardless of clinical stage or CD4 count. Option B+ is expected to have benefits for HIV-infected women, their HIV-exposed infants, and their HIV-uninfected male sex partners. However, these benefits hinge on early uptake of prevention of mother-to-child transmission, good adherence, and long-term retention in care. The Prevention of mother-to-child transmission Uptake and REtention (PURE) study is a 3-arm cluster randomized controlled trial to evaluate whether clinic- or community-based peer support will improve care-seeking and retention in care by HIV-infected pregnant and breastfeeding women, their HIV-exposed infants, and their male sex partners, and ultimately improve health outcomes in all 3 populations. We describe the PURE Malawi Consortium, the initial work conducted to inform the trial and interventions, the trial design, and the analysis plan. We then discuss concerns and expected contributions to Malawi and the region.


Subject(s)
Family , HIV Infections/transmission , Infectious Disease Transmission, Vertical/prevention & control , Patient Compliance , Peer Group , Pregnancy Complications, Infectious/prevention & control , Anti-HIV Agents/therapeutic use , Female , HIV Infections/complications , HIV Infections/drug therapy , HIV Infections/prevention & control , Humans , Infant, Newborn , Malawi , Pregnancy , Pregnancy Complications, Infectious/drug therapy , Sample Size
7.
PLoS One ; 9(8): e104178, 2014.
Article in English | MEDLINE | ID: mdl-25153084

ABSTRACT

BACKGROUND: PEARLS, a large scale trial of antiretroviral therapy (ART) for HIV (n = 1,571, 9 countries, 4 continents), found that a once-daily protease inhibitor (PI) based regimen (ATV+DDI+FTC), but not a once-daily non-nucleoside reverse transcriptase inhibitor/nucleoside reverse transcriptase inhibitor (NNRTI/NRTI) regimen (EFV+FTC/TDF), had inferior efficacy compared to a standard of care twice-daily NNRTI/NRTI regimen (EFV+3TC/ZDV). The present study examined non-adherence in PEARLS. METHODS: Outcomes: non-adherence assessed by pill count and by self-report, and time to treatment failure. Longitudinal predictors: regimen, quality of life (general health perceptions  =  QOL-health, mental health  =  QOL-mental health), social support, substance use, binge drinking, and sexual behaviors. "Life-Steps" adherence counseling was provided. RESULTS: In both pill-count and self-report multivariable models, both once-a-day regimens had lower levels of non-adherence than the twice-a-day standard of care regimen; although these associations attenuated with time in the self-report model. In both multivariable models, hard-drug use was associated with non-adherence, living in Africa and better QOL-health were associated with less non-adherence. According to pill-count, unprotected sex was associated with non-adherence. According to self-report, soft-drug use was associated with non-adherence and living in Asia was associated with less non-adherence. Both pill-count (HR = 1.55, 95% CI: 1.15, 2.09, p<.01) and self-report (HR = 1.13, 95% CI: 1.08, 1.13, p<.01) non-adherence were significant predictors of treatment failure over 72 weeks. In multivariable models (including pill-count or self-report nonadherence), worse QOL-health, age group (younger), and region were also significant predictors of treatment failure. CONCLUSION: In the context of a large, multi-national, multi-continent, clinical trial there were variations in adherence over time, with more simplified regimens generally being associated with better adherence. Additionally, variables such as QOL-health, regimen, drug-use, and region play a role. Self-report and pill-count adherence, as well as additional psychosocial variables, such QOL-health, age, and region, were, in turn, associated with treatment failure.


Subject(s)
Anti-Retroviral Agents/administration & dosage , HIV Infections/drug therapy , Patient Compliance/psychology , Adult , Anti-Retroviral Agents/therapeutic use , Female , Humans , Male , Middle Aged , Models, Theoretical , Psychology , Quality of Life , Social Support , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...